Biotech | April 29, 2022
Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
It is expanding the diagnostics business footprint in North East India
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
This facility will design & develop instruments, perform product reliability performance testing and verification
TSCS appeals to the Govt. of Telangana to release a G.O for mandatory antenatal test - HbA2 for every pregnant woman to help prevent the birth of Thalassemia Major Children for the well-being of their family & Telangana State
Beyond the technical leadership from F1, the collaboration will bring a specific focus on the people dimension of high performance
The demand for high-quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures
Tembo and UFlex-Asepto have co-developed 100% renewable and recyclable paper straw solution that will be food grade, moisture-resistant and made from sustainably sourced papers
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Subscribe To Our Newsletter & Stay Updated
